Immunicum AB (1YG0) Stock Statistics & Valuation Metrics

Immunicum AB has a market cap or net worth of €34.98M. The enterprise value is €362.62M.

Immunicum AB has 52,084,580 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunicum AB’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.24%.

The current PE Ratio of Immunicum AB is ―. Immunicum AB’s PEG ratio is 0.07.

In the last 12 months, Immunicum AB had revenue of 0.00 and earned -128.40M in profits. Earnings per share was -2.64.

In the last 12 months, operating cash flow was -68.00M and capital expenditures -544.00K, giving a free cash flow of -68.54M billion.

Immunicum AB pays an annual dividend of ―, resulting in a dividend yield of ―

Immunicum AB upcoming earnings date is Feb 11, 2026, Before Open (Confirmed).

Immunicum AB as a current ratio of 4.29, with Debt / Equity ratio of 0.72%

In the past 12 months, Immunicum AB has paid 0.00 in taxes.

Immunicum AB EV to EBITDA ratio is -2.49, with an EV/FCF ratio of -3.68.

Immunicum AB has €37.56M in cash and marketable securities with €4.12M in debt, giving a net cash position of €33.44M billion.

Gross margin is -48.64%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Immunicum AB is ―, which is 11.43% higher than the current price. The consensus rating is Hold